Phase 2 Kidney Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older at the time of screening
• People who have given written consent to participate before any study-related procedures begin
• People with a life expectancy of at least 12 months
• People diagnosed with renal cell carcinoma (a type of kidney cancer) confirmed by both imaging scans and tissue testing
• People whose kidney cancer is at an early stage (T1 or T2a, with no spread to lymph nodes or other parts of the body)
• People with 1 or 2 tumours that are mostly solid (more than 80% solid tissue)
• People whose medical team (a specialist tumour board) has determined that partial kidney removal surgery is not a suitable option due to factors such as the tumour's position, medical conditions, or anaesthesia risks
• People whose medical team has determined that heat- or cold-based tumour destruction (thermal ablation) is not a suitable option due to the tumour's location or technical challenges
• People whose medical team has determined that long-term watchful waiting is not appropriate given the tumour's size or growth
• People whose medical team has determined that full kidney removal surgery is not ideal due to other health conditions
• People whose tumour can be measured using standard imaging guidelines (RECIST 1.1 criteria)
• People who do not have tumours in both kidneys
• Women who could become pregnant must have a negative pregnancy test before joining; women who are breastfeeding cannot participate
• People with blood test results meeting specific levels: haemoglobin at least 9.0 g/dL, neutrophil count at least 1.5 x 10⁹/L, lymphocyte count at least 1.0 x 10⁹/L, and platelet count at least 75 x 10⁹/L
• People whose kidneys are functioning well enough, with a filtration rate (GFR) of at least 45 mL/min/1.73 m²
• People who are generally active and able to care for themselves (ECOG performance status of 0 or 1)
• People whose initial angiogram (a specialised blood vessel imaging test) confirms the tumour can be targeted with the treatment without the treatment flowing into unintended areas

Who may not be able to join:

• People who have any medical reason they cannot safely undergo angiography (blood vessel imaging) or catheter placement into the kidney arteries
• People whose screening angiogram shows blood flow connecting to the digestive tract in a way that cannot be corrected
• People whose screening angiogram shows the tumour cannot be accurately targeted with the required treatment dose
• People whose screening angiogram suggests the treatment would damage enough healthy kidney tissue to reduce kidney filtration rate below 45 mL/min/1.73 m²
• People whose screening angiogram shows contrast fluid immediately flowing into kidney veins upon injection (a sign of problematic shunting)
• People whose cancer has spread beyond the kidney, including to nearby lymph nodes larger than 1.5 cm or to the lungs above certain size thresholds
• People with cancer that has spread to the brain, the lining of the brain or spinal cord, or who are compressing the spinal cord
• People whose tumour has grown into the kidney's veins, arteries, or urine-collecting structures
• People who have previously had radiation treatment to the abdomen, including to the kidney tumour itself
• People currently receiving or who have received treatment for kidney cancer in another clinical trial within the past 6 months (observational studies or non-interventional follow-up may be exceptions — confirm with trial site)
• People with a history of active primary or acquired immune system deficiency (such as certain immune conditions)
• People who have or have had a ureteral stent (a small tube placed in the urinary tract) in the kidney being treated
• People with a history of another cancer within the past three years, with some exceptions for certain low-risk, early-stage cancers (confirm with trial site)
• People who have had a major surgical procedure within 28 days before enrolment
• People with a history of severe allergic reactions or intolerance to contrast dyes, sedatives, narcotics, or atropine that cannot be managed medically
• People with an active infection at the time of enrolment
• Women who are pregnant or breastfeeding, or women of reproductive potential who are not willing to use effective contraception from screening until 6 months after treatment
• People with serious unstable health conditions, including but not limited to uncontrolled heart failure, uncontrolled high blood pressure, unstable chest pain, uncontrolled heart rhythm problems, active lung disease, serious ongoing digestive conditions, or mental health or social circumstances that would make it difficult to safely participate
• People with a history of lung insufficiency, shown by blood oxygen levels below 90%
• People who have only one kidney
• People who would not be able to follow the requirements of the study protocol

Important: Always verify eligibility with the trial site directly before applying.